Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | XENE |
---|---|---|
09:32 ET | 546 | 37.6 |
09:43 ET | 400 | 37.35 |
09:48 ET | 100 | 37.355 |
09:50 ET | 100 | 37.13 |
09:54 ET | 798 | 37.33 |
09:56 ET | 900 | 37.47 |
09:57 ET | 100 | 37.585 |
10:01 ET | 100 | 37.47 |
10:03 ET | 100 | 37.61 |
10:06 ET | 419 | 37.6 |
10:12 ET | 652 | 37.37 |
10:19 ET | 6648 | 37.375 |
10:21 ET | 200 | 37.315 |
10:24 ET | 3383 | 37.13 |
10:30 ET | 100 | 37.21 |
10:32 ET | 200 | 37.185 |
10:35 ET | 128 | 37.2 |
10:42 ET | 100 | 37.21 |
10:44 ET | 100 | 37.16 |
10:51 ET | 200 | 37.23 |
10:53 ET | 100 | 37.16 |
10:55 ET | 1301 | 37.1 |
10:57 ET | 784 | 37 |
11:09 ET | 984 | 37.205 |
11:20 ET | 500 | 37.4 |
11:22 ET | 1181 | 37.5 |
11:26 ET | 400 | 37.48 |
11:31 ET | 5027 | 37.48 |
11:36 ET | 100 | 37.46 |
11:40 ET | 100 | 37.43 |
11:42 ET | 246 | 37.46 |
11:54 ET | 609 | 37.37 |
11:56 ET | 400 | 37.34 |
12:00 ET | 100 | 37.345 |
12:02 ET | 705 | 37.245 |
12:03 ET | 200 | 37.17 |
12:05 ET | 500 | 37.19 |
12:07 ET | 699 | 37.2006 |
12:12 ET | 205 | 37.18 |
12:14 ET | 600 | 37.14 |
12:16 ET | 200 | 37.02 |
12:18 ET | 2014 | 37.02 |
12:20 ET | 1720 | 37.085 |
12:21 ET | 246 | 37.1 |
12:23 ET | 600 | 37.105 |
12:25 ET | 126 | 37.105 |
12:32 ET | 1400 | 37.02 |
12:34 ET | 200 | 37.02 |
12:36 ET | 866 | 37.035 |
12:39 ET | 500 | 37.01 |
12:41 ET | 463 | 37.025 |
12:43 ET | 100 | 36.97 |
12:45 ET | 1324 | 37.06 |
12:48 ET | 600 | 36.98 |
12:52 ET | 100 | 36.92 |
12:56 ET | 535 | 36.83 |
12:59 ET | 100 | 36.77 |
01:03 ET | 400 | 36.87 |
01:10 ET | 400 | 36.895 |
01:21 ET | 810 | 36.79 |
01:26 ET | 200 | 36.76 |
01:28 ET | 100 | 36.76 |
01:32 ET | 500 | 36.74 |
01:33 ET | 540 | 36.7284 |
01:35 ET | 634 | 36.8 |
01:37 ET | 805 | 36.86 |
01:39 ET | 200 | 36.86 |
01:44 ET | 300 | 36.81 |
01:46 ET | 140 | 36.73 |
01:48 ET | 100 | 36.77 |
01:51 ET | 100 | 36.735 |
01:53 ET | 100 | 36.74 |
01:55 ET | 300 | 36.81 |
01:57 ET | 100 | 36.775 |
02:00 ET | 124 | 36.775 |
02:04 ET | 1600 | 36.86 |
02:06 ET | 610 | 36.8 |
02:15 ET | 415 | 36.71 |
02:18 ET | 200 | 36.68 |
02:20 ET | 100 | 36.63 |
02:24 ET | 100 | 36.61 |
02:26 ET | 100 | 36.66 |
02:29 ET | 100 | 36.62 |
02:31 ET | 100 | 36.68 |
02:33 ET | 200 | 36.69 |
02:38 ET | 1400 | 36.7 |
02:40 ET | 300 | 36.73 |
02:44 ET | 100 | 36.75 |
02:45 ET | 500 | 36.81 |
02:47 ET | 100 | 36.83 |
02:49 ET | 1095 | 36.96 |
02:51 ET | 900 | 36.95 |
02:56 ET | 703 | 36.92 |
02:58 ET | 200 | 36.96 |
03:00 ET | 501 | 37 |
03:02 ET | 1979 | 36.925 |
03:03 ET | 100 | 36.92 |
03:07 ET | 800 | 36.885 |
03:09 ET | 225 | 36.841 |
03:12 ET | 1298 | 36.88 |
03:16 ET | 300 | 36.85 |
03:20 ET | 820 | 36.93 |
03:21 ET | 4900 | 37.01 |
03:23 ET | 5234 | 37.03 |
03:25 ET | 1600 | 37.025 |
03:27 ET | 8508 | 37.005 |
03:30 ET | 1102 | 36.975 |
03:32 ET | 1900 | 36.99 |
03:34 ET | 1300 | 36.93 |
03:38 ET | 1000 | 36.91 |
03:39 ET | 800 | 36.935 |
03:41 ET | 1073 | 36.92 |
03:43 ET | 500 | 36.92 |
03:45 ET | 300 | 36.92 |
03:48 ET | 900 | 36.82 |
03:50 ET | 1235 | 36.82 |
03:54 ET | 805 | 36.78 |
03:56 ET | 2802 | 36.64 |
03:57 ET | 2409 | 36.665 |
03:59 ET | 36794 | 36.56 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Xenon Pharmaceuticals Inc | 2.8B | -13.5x | --- |
SpringWorks Therapeutics Inc | 2.9B | -7.2x | --- |
MoonLake Immunotherapeutics | 2.7B | -53.5x | --- |
Geron Corp | 2.6B | -12.0x | --- |
Biohaven Ltd | 3.1B | -5.0x | --- |
IDEAYA Biosciences Inc | 2.7B | -16.9x | --- |
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -13.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.